At EURETINA 2026, Roger Goldberg, MD, MBA, explains why EYP-1901 missed LUGANO's primary endpoint despite matched anatomy, clean safety and a 42% cut in treatment burden.
Roger A. Goldberg, MD, MBA
Advertisement
Bay Area Retina Associates in Walnut Creek, California
Articles by Roger A. Goldberg, MD, MBA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
2026 Nobel Prize in Physiology or Medicine awarded for optogenetics discovery
2
EURETINA 2026: Eyestem interim Phase 2 results for clinical study of Eyecyte-RPE for GA secondary to dry AMD
3
EURETINA 2026: Real-world evidence on retinal biosimilars
4
EURETINA 2026: 3 gene therapy programmes for nAMD approaching phase 3 readouts
5